These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7586338)

  • 21. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
    Teo KK; Burton JR; Buller CE; Plante S; Catellier D; Tymchak W; Dzavik V; Taylor D; Yokoyama S; Montague TJ
    Circulation; 2000 Oct; 102(15):1748-54. PubMed ID: 11023927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
    Furberg CD; Adams HP; Applegate WB; Byington RP; Espeland MA; Hartwell T; Hunninghake DB; Lefkowitz DS; Probstfield J; Riley WA
    Circulation; 1994 Oct; 90(4):1679-87. PubMed ID: 7734010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
    Downs JR; Clearfield M; Tyroler HA; Whitney EJ; Kruyer W; Langendorfer A; Zagrebelsky V; Weis S; Shapiro DR; Beere PA; Gotto AM
    Am J Cardiol; 2001 May; 87(9):1074-9. PubMed ID: 11348605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).
    Vigen C; Hodis HN; Selzer RH; Mahrer PR; Mack WJ
    Am J Cardiol; 2005 Jun; 95(11):1277-82. PubMed ID: 15904629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
    Domanski M; Tian X; Fleg J; Coady S; Gosen C; Kirby R; Sachdev V; Knatterud G; Braunwald E
    Am J Cardiol; 2008 Oct; 102(8):1023-7. PubMed ID: 18929703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
    Shukla A; Sharma MK; Jain A; Goel PK
    Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
    Treasure CB; Klein JL; Weintraub WS; Talley JD; Stillabower ME; Kosinski AS; Zhang J; Boccuzzi SJ; Cedarholm JC; Alexander RW
    N Engl J Med; 1995 Feb; 332(8):481-7. PubMed ID: 7830728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population.
    Clearfield M; Whitney EJ; Weis S; Downs JR; Shapiro DR; Stein EA; Watson DJ; Langendörfer A; Beere PA; Stamler J; Gotto AM
    J Cardiovasc Risk; 2000 Apr; 7(2):125-33. PubMed ID: 10879416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
    Mack WJ; Azen SP; Dunn M; Hodis HN
    Control Clin Trials; 1997 Apr; 18(2):168-79. PubMed ID: 9129860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients.
    Barlow CW; Friedman BM; Myburgh DP; Soicher ER; Steenkamp WF; Smith DH
    Cardiovasc Drugs Ther; 1990 Oct; 4(5):1389-94. PubMed ID: 2278874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial.
    Hodis HN; Mack WJ; LaBree L; Selzer RH; Liu C; Liu C; Alaupovic P; Kwong-Fu H; Azen SP
    Ann Intern Med; 1996 Mar; 124(6):548-56. PubMed ID: 8597317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population.
    Gotto AM
    Am J Cardiol; 2000 Jun; 85(12A):8E-14E. PubMed ID: 10858488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
    Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.
    Bradford RH; Shear CL; Chremos AN; Dujovne C; Franklin FA; Hesney M; Higgins J; Langendörfer A; Pool JL; Schnaper H
    Am J Cardiol; 1990 Sep; 66(8):44B-55B. PubMed ID: 2206036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS).
    Dumont JM
    Control Clin Trials; 1993 Jun; 14(3):209-28. PubMed ID: 8339551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.